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Abstract  
 
Background: Many single-nucleotide polymorphisms (SNPs) have been described as putative 
risk factors for melanoma.  
Objective: To validate the most prominent genetic risk loci in an independent Greek melanoma 
case-control dataset and to assess their cumulative effect solely or combined with established 
phenotypic risk factors on individualized risk prediction. 
Methods: We genotyped 59 SNPs in 800 patients and 800 controls and tested their association 
with melanoma using logistic regression analyses. We constructed a weighted genetic risk score 
(GRSGWS) based on SNPs that showed genome-wide significant (GWS) association with 
melanoma in previous studies and assessed their impact on risk prediction 
Results: Fifteen independent SNPs from 12 loci were significantly associated with melanoma (p 
< 0.05). Risk score analyses yielded an odds ratio: OR=1.36 per standard deviation increase of 
the GRSGWS (p=1.1x10
-7
). Individuals in the highest 20% of the GRSGWS had a ~1.88-fold 
increase in melanoma risk compared with those in the middle quintile. By adding the GRSGWS to 
a phenotypic risk model, including eye, hair and skin color, phototype, tanning ability, sex and 
age, the C-stastistic increased from 0.764 to 0.775 (p=0.007).  
Conclusion: The GRSGWS is associated with melanoma risk and achieves a modest improvement 
in risk prediction when added in the phenotypic risk model.  
 
Keywords: cutaneous melanoma, genetic association, GWAS, genetic risk score, multivariable 
prediction model, non-genetic risk factors, risk assessment. 
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Introduction  
 
Cutaneous melanoma (CM) is a potentially lethal skin malignancy, showing a continuously 
increasing incidence rate in Caucasians worldwide. The development of melanoma is a complex 
process involving the interplay of environmental, phenotypic and genetic risk factors. The role of 
genetic factors in melanomagenesis has been recognized since the identification of CDKN2A 
(Hussussian et al., 1994; Kamb et al., 1994) and CDK4 (Puntervoll et al., 2013; Soufir et al., 
1998; Zuo et al., 1996) as high penetrance susceptibility genes. Recent efforts have contributed to 
the discovery of an additional number of high risk genes, such as BAP1, MITF, TERT, POT1 and 
other shelterin complex GENES (ACD and TERF2IP) (Aoude et al., 2015; Bertolotto et al., 
2011; Harbour et al., 2010; Horn et al., 2013; Robles-Espinoza et al., 2014; Shi et al., 2014; 
Yokoyama et al., 2011). Genetic association studies, i.e., genome-wide association studies 
(GWAS) and candidate-gene studies have also revealed numerous common SNPs exerting more 
modest risk effects with more than 20 loci, including 5 new, that surpassed the genome wide 
significance threshold (i.e. p < 5x10
-8
) for association with CM in recent GWAS (Law et al., 
2015). These studies have established the association of CM with pigmentation (MC1R, TYR and 
SLC45A2) and nevi-associated genes (MTAP, PLA2G6), as well as with loci potentially 
implicated in apoptosis (CASP8), DNA repair (PARP-1, ATM), metabolism (FTO) and more 
recently, telomerase length (TERT/CLPTM1L) (Barrett et al., 2011; Iles et al., 2013; Ward et al., 
2012). Most reported genetic variants have been summarized in an updated field synopsis of 
published genetic association studies (Antonopoulou et al., 2015; Chatzinasiou et al., 2011; ).  
This growing list of melanoma risk loci needs to be validated in large and independent datasets 
from other populations. In this context, the Greek population is of particular interest since it has a 
reportedly low incidence of melanoma compared to other European countries despite a high 
Page 5 of 36 Journal of Investigative Dermatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
5 
 
degree of ambient ultraviolet exposure year-round (Ferlay et al., 2013). The aim of this study was 
to validate the extensive set of SNPs that have been previously associated with CM risk in an 
independent sample of melanoma patients and healthy controls from Greece. In addition, we 
assessed the cumulative impact of the genetic variants on melanoma risk prediction by calculating 
a weighted GRS and combined this GRS with non-genetic, phenotypic risk factors. 
 
RESULTS 
 
Demographics and phenotypic traits of the 800 patients with CM and 800 control subjects 
included in this study are shown in Table S1. Fifty-five of 59 SNPs were genotyped with call 
rates ≥97%. One SNP deviated from Hardy-Weinberg equilibrium in the control population 
(rs1129038, p=1.6x10
-4
, in HERC2) and one SNP (rs149617956 in MITF) was monomorphic. 
These SNPs were excluded from subsequent analyses. Fifty-three SNPs were considered in the 
final analysis, of which 26 were genome-wide significantly associated with CM based on the 
MelGene meta-analysis or from independent GWAS if they had not been included in the 
MelGene meta-analysis. Calculation of the linkage disequilibrium r
2
 metric and conditional 
analyses revealed that all SNPs represent independent loci (data not shown).  
 
The median power to detect the original effects as reported previously for the 53 SNPs based on 
the observed risk allele frequency in the control group was 0.455 (interquartile range 0.226 to 
0.725) and the mean power was 0.495. For the 26 SNPs that were found to be GWS, the median 
and mean of the power estimates were 0.668 (0.380 to 0.906) and 0.634, respectively. Based on 
power calculation, it is expected that our study yielded 26 statistically significant associations 
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among the 53 tested SNPs. Fifteen SNPs thereof were statistically significantly associated with 
CM in our study. Sixteen of the 26 robustly GWS variants were expected to be associated in our 
study, and 11 SNPs were indeed nominally significant (p=0.07 for probability test). 
 
Association between putative risk SNPs and melanoma  
 
Logistic regression analyses assuming an additive model revealed 15 SNPs with nominally 
significant (p<0.05) effect size estimates showing the same direction of effect as previously 
described (Table 1, Table S2). This included 10 SNPs that had been reported to be associated 
with CM with GWS, specifically rs16891982, rs1805007, rs401681, rs1885120, rs4636294, 
rs10931936, (Antonopoulou et al., 2015) as well as rs12918773, rs10739221, rs4778138, 
rs17119490 (Barrett et al., 2011; Bishop et al., 2009; Law et al., 2015). Among the five new loci 
identified in the most recent GWAS meta-analysis (Law et al., 2015) the intergenic SNP with 
rs10739221 near TMEM38B, ZNF462 and RAD23B as well as the SNP with rs4778138 in 
OCA2 at 15q13.1 were significantly associated with CM in our dataset showing effect estimates 
into the same direction as in Law et al. (Law et al., 2015) (rs10739221: OR=1.209, p=0.015, 
rs4778138: OR=0.833, p=0.014, Table 1).  
 
Figure S1 and Table S2 summarize the additive ORs of the eligible SNPs with melanoma risk in 
our study as well as the ORs reported in the original reference source. Overall, we observed a 
modest correlation of our effect size estimates and those reported previously (r
2
=0.41, p=0.038 
for the previously GWS SNPs; r
2
=0.34, p=0.0130 for all 53 SNPs). The median risk allele 
frequency for the 53 risk alleles was 40.95% (IQR, 14.14-64.72%) in the Greek population. 
Page 7 of 36 Journal of Investigative Dermatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
7 
 
Compared to a set of European populations derived from the 1KG project panel the correlation of 
risk allele frequencies was very high (r
2
=0.97, P<0.0001) (Figure S2, Table S3). 
 
Association between the GRS and melanoma 
 
Risk score analyses yielded an OR=1.36 (95% CI: 1.21-1.52) per standard deviation increase of 
the GRSGWS (p=1.1x10
-7
). The magnitude and the strength of the association were comparable for 
GRSALL (OR = 1.39 (95% CI: 1.23-1.55, p=3.2x10
-8
); Table S4). The adjusted ORs for melanoma 
showed a linear relationship with increasing percentiles of the GRS (trend test result for quintiles 
of GRSGWS: p=1.4x10
-7
, GRSALL: p=3.2x10
-9
) (Figure 1, Table S5). The OR for individuals in the 
lowest quintile was 0.73 (95% CI: 0.50-1.05) and for participants in the highest quintile 1.88 
(95% CI: 1.29-2.74) compared with study participants in the middle quintile (Table S5). 
 
The discriminative ability of the GRSGWS as measured by the C-statistic was 0.575 (95% CI: 
0.549-0.604). When we considered traditional non-genetic risk factors only (i.e. sex, age, eye, 
hair and skin colour, phototype and tanning ability) the C-statistic was 0.764 (95% CI: 0.741-
0.787). Upon combination of all genetic and non-genetic risk factors the C-statistic including 
GRSGWS increased to 0.775 (95% CI: 0.752-0.797, p for area under the receiver-operating 
characteristics curve (AUC) comparison=0.007). The results were similar when GRSAll was 
considered (Table 2). The root mean square error (RMSE) in the 5-fold cross-validation approach 
ranged from 0.453 to 0.465 for the non-genetic model. When the GRSGWS was added root mean 
square error ranged from 0.442 to 0.486. In both models cross-validation indicates a very good 
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model fit. Moreover, calibration assessment revealed that the predicted probabilities agree with 
the observed probabilities (Hosmer-Lemeshow test p-value=0.77). 
 
A sensitivity analysis excluding all participants with missing values yielded comparable results. 
A total of 1,285 participants were considered and the C-statistic for the non-genetic model was 
0.728 (95% CI: 0.701-0.755). The model including GRSGWS yielded a C-statistic of 0.741 (95% 
CI: 0.741-0.767). 
 
The age-stratified association results of the GRS and CM are summarized in Table S6. As shown, 
the interaction between GRS and age was not significant (p ≥ 0.05). 
 
DISCUSSION  
 
We comprehensively assessed over 50 putative melanoma risk SNPs in a large and independent 
Greek dataset. Furthermore, we showed that the inclusion of common genetic variants in a CM 
prediction model leads to a modest improvement of its predictive abilities compared to a risk 
prediction model based on non-genetic factors only.  
 
The selection of variants was mainly based on the MelGene field synopsis of genetic associations 
of melanoma, which systematically curates and meta-analyzes all published melanoma-associated 
variants (Antonopoulou et al., 2015). Most of the variants that showed significant effects in our 
dataset pertained to genes controlling pigmentary traits. This can be explained by the fact that the 
Page 9 of 36 Journal of Investigative Dermatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
9 
 
majority of these variants seem to exert moderate or even large effects on disease risk, thus our 
study had sufficient power to detect them. Eleven of the 26 variants reported as genome wide 
significant (p < 5 × 1 10
−8
) in the original GWAS (Amos et al., 2011; Barrett et al., 2011; Bishop 
et al., 2009; Brown et al., 2008; Iles et al., 2013; Macgregor et al., 2011; Teerlink et al., 2012) or 
subsequent meta-analysis in MelGene were replicated in our cohort at a nominal significant level. 
Among the 5 newly identified genetic loci in a recent two-stage GWAS meta-analysis (Law et al., 
2015) involving 15,990 cases and 26,409 controls, 1 intergenic locus at 9q31.2 (rs10739221), at 
the proximity of TMEM38B, ZNF462 and the nucleotide excision repair gene RAD23B, was 
replicated (Masutani et al., 1994). In addition, the SNP in OCA2 at 15q13.1, a potential 
determinant of eye color, that was found GWS for melanoma in Law et al (Law et al., 2015), was 
also replicated in our study. 
 
Several risk prediction models for melanoma using conventional phenotypic or clinical factors 
have been published, in an effort to better assess individual risk and develop more targeted 
prevention plans (Olsen et al., 2015; Vuong et al., 2014). Most of these prediction tools achieve 
modest discriminatory efficacy, yet their performance is variable upon independent validation due 
to poor calibration, lack of reproducible standardized assessment items, or heterogeneity in the 
definition of predictor variables (Olsen et al., 2015). The discovery of multiple genetic variants 
that are associated with melanoma risk along with the constantly decreasing genotyping costs, 
have led to the development of genetic risk models with the potential advantage of identifying 
individuals at risk who may not be considered as so based on phenotypic characterization or 
exposure data. In the present study, we attempted to summarize the available genetic information 
by constructing a GRS using evidence from SNPs that have been associated with melanoma. We 
found that the risk for melanoma was associated with GRS even when adjusting for traditional 
risk factors, such as skin, hair and eye color. The results were similar for our primary model 
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analysis (GRS consisting of only GWS variants) and a secondary model consisting of all 53 
analyzed variants. Our multivariable prediction model combining the most robust genetic factors 
by means of GWS association and phenotypic or non-genetic factors yielded a summary C-
statistic of 0.775. The statistically significant, but marginal increase of 0.011 for the C statistic 
achieved by the addition of genetic susceptibility variants to a non-genetic model, does not 
strongly support the clinical utility of genetic variant profiling in individualized risk prediction.  
 
Previous risk models using various clinical risk factors yielded AUCs ranging from 0.62 to 0.86 
(Davies et al., 2015; Vuong et al., 2014). However, there are limited published prediction models 
incorporating genetic factors in CM (Cust et al., 2013; Fang et al., 2013; Penn et al., 2014; 
Stefanaki et al., 2013; Whiteman and Green, 2005). Three studies focused on the effect of MC1R 
in melanoma prediction (Cust et al., 2013; Penn et al., 2014; Whiteman and Green, 2005). 
Whiteman and Greene found that MC1R variants substantially increased melanoma risk when 
present in persons of olive skin color (Whiteman and Green, 2005). Cust et al concluded that 
MC1R is a better predictor than pigmentation characteristics in early-onset melanoma (Cust et al., 
2013), while Penn et al reported that the addition of MC1R genotype information to the baseline 
model resulted in a slight but statistically significant improvement in risk prediction, especially in 
nevus-prone patients (Penn et al., 2014). In our previous study (Stefanaki et al., 2013) the 
addition of 8 SNPs with nominal significance to a clinical model did not substantially improve 
melanoma risk prediction. In the present study, as well as in a recently published study of a GRS 
based on 11 SNPs tested in 1,804 melanoma patients and 1,026 controls (Fang et al., 2013), the 
discrimination ability of the conventional phenotypic risk model increased when the GRS was 
incorporated to this model (C-statistic reaching 0.775 in our study and 0.69 in the study by Fang 
et al). Although differences between the two studies with regards to study design and population 
do not allow for direct comparison, the association of GRS with CM risk was significant in both 
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cases (OR=1.36, 95% CI: 1.21-1.59 for our GRSGWS model compared to 1.12, 95% CI: 1.06-1.18, 
adjusting for similar risk factors) (Fang et al., 2013).  
 
Our sample represents the largest series of melanoma patients studied in Greece. We constructed 
our main GRS model based on established independent signals that showed genome-wide 
significance in previous studies, regardless of how they performed in our Greek case-control 
study. To this end, we avoided data overfitting by models that take in account only those variants 
with statistical significance in our population. In addition, we applied the checklist of the 
TRIPOD (Collins et al., 2015) and GRIPS (Janssens et al., 2011) statement recommendations, 
which aim to strengthen the transparency and homogeneity of reporting of multivariable and 
genetic risk prediction models among studies. Certain limitations apply to our study, with 
foremost the small size of our cohort. Several values concerning phenotypic characteristics, 
including the number of nevi, are missing due to variations in the information and questionnaires 
used by the participating centers. In addition, we did not include family history as a risk factor 
since this information was not available for the vast majority of our control samples. Risk 
prediction algorithms in other cancers, i.e., breast cancer suggest that the inclusion of family 
history in a polygenic risk score leads to further substantial improvement of the risk prediction 
model (Mavaddat et al., 2015; So et al., 2011). In addition, we did not take into account possible 
gene-environment interactions  or gene-gene interactions. Incorporating SNPs with a stronger 
evidence of association after fine mapping of relevant genomic regions (Barrett et al., 2015), in 
combination with intermediate or high risk genes might further improve the risk stratification of 
the GRS. Although we tested the internal validity of our prediction models, genetic predictive 
models for melanoma would benefit from additional external validation testing in similar 
(southern European) or other populations. 
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In conclusion, we replicated several genetic variants that confer susceptibility for melanoma in 
our population, confirming the polygenic nature of melanoma. We also explored the predictive 
capability of a GRS, which incorporated several GWS variants reported in the literature. The 
GRS was not superior from a phenotypic risk model, and its combination with phenotypic risk 
variables only slightly enhanced the discriminatory ability of our model. Based on our results, we 
cannot support the implementation of genetic variant profile in risk prediction models of 
melanoma. Independent studies in other populations will be required to adequately validate these 
findings.  
 
MATERIALS AND METHODS 
 
Study Population 
 
The Greek sample consisted of patients with a histologically confirmed diagnosis of invasive 
melanoma at A. Sygros Hospital, a large referral center of melanoma and skin cancer in Athens 
and a collaborating oncological center (Laiko Hospital, Oncology Clinic), from 2000 to 2014. 
Both centers receive the majority of melanoma patients from Athens, thus consisting a 
representative sample size of the Greek population. 
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The control subjects were blood donors from a blood donation center in Athens and individuals 
with minor skin diseases and no history of skin malignancy, attending the outpatient service of 
our hospital. All subjects were above the age of 18. 
 
Demographic variables, pigmentation traits (eye, hair, and skin color), skin phototype and tanning 
ability were obtained through a questionnaire that was given to the participants and clinical 
examination by a certified dermatologist. The study protocol was approved by the Scientific and 
Ethics Committee of A. Sygros Hospital; all participating individuals gave written informed 
consent prior to participating in the study. 
 
SNP selection  
 
Fifty nine variants were genotyped. Most of the SNPs (n=52) to be genotyped were selected from 
MelGene (www.melgene.org), a continuously updated database that collects all SNPs associated 
with melanoma risk (Antonopoulou et al., 2015; Athanasiadis et al., 2014; Chatzinasiou et al., 
2011). We further included in our study 7 GWAS SNPs from arecent GWAS meta-analysis, 
which were tested in our cohort as part of the replication phase (Law et al., 2015). A MelGene 
SNP should have a p-value <0.05 and strong evidence of credibility using Venice criteria (grade 
A) (Ioannidis et al., 2008) or should be GWS (p<5x10
-8
) if it had emerged from a GWA study to 
be included in our study. Thirteen out of the 52 variants selected from MelGene database were 
included in the analysis because of their strong biological correlation with important melanoma 
pathways, even if they did not meet the above criteria. 
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 DNA isolation, Genotyping and Quality control 
 
Genomic DNA was isolated from peripheral blood using the QIAamp DNA blood mini kit 
(Qiagen). A total of 100ng from each DNA sample were used to genotype the selected SNPs, 
using the Sequenom iPLEX assay (Sequenom, Hamburg, Germany) (Gabriel et al., 2009). Our 
quality control criteria included the inclusion of SNPs with a genotype call rate of 97% or higher 
and no deviation from Hardy-Weinberg equilibrium (p< 8,5x10
-4
). We also excluded participants 
that had available <90% of SNPs genotyped. 
 
Statistical Analysis 
 
The association of each SNP with CM was computed using logistic regression and assuming an 
additive model. Adjustment for multiple testing was conducted using Bonferroni correction for 
the effective number of SNPs included in the analysis (cut off: p=8.5x10
-4
). Additionally, we 
estimated: a) the correlation of risk allele frequencies between the Europeans from a panel 
derived from the 1000 Genomes (1KG) project (“EUR” population, Phase 3 v5) and the Greek 
population and b) the correlation of the effect size estimates found in the Greek population with 
those reported previously. Minor allele frequencies from the 1KG panel were extracted from 
SNiPA (Arnold et al., 2015), a genetic variant-centered annotation browser.  
 
Finally, we calculated Linkage Disequilibrium metrics (r
2
) using PLINK 1.07, for SNPs located 
in the same locus. We considered SNPs with r
2
<0.6 as independent. For SNP pairs with r
2 
ranging 
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from 0.3 to 1 we performed additional conditional logistic regression analyses to ensure 
independence. 
 
Power Calculation 
 
The QUANTO software was used for power calculations (http://biostats.usc.edu/Quanto.html). 
For every SNP, the power Gi to detect each of the described effects at a = 0.05 level given the 
observed risk allele frequency in the Greek sample, was calculated assuming an additive (per-
allele) genetic model. The sum of the power estimates corresponds to the number of variants that 
would be expected to replicate.  
 
GRS calculation and melanoma risk prediction analyses 
 
We constructed two different weighted GRS. Primary GRS was based on SNPs that have been 
found GWS from MelGene meta-analysis (n=11), 7 SNPs from Law et al. (Law et al, 2015) and 8 
SNPs from independent GWAS that did not have sufficient datasets to be meta-analyzed in 
MelGene (GRSGWS). A secondary GRS consisted of all analysed SNPs (GRSALL) (n=53 
successfully genotyped of the 59) (Table S2). The GRS represents a sum of the number of effect 
alleles weighted by their effect size estimates, specifically by their beta coefficients. The effect 
estimates were derived from the MelGene meta-analysis or independent published GWAS (Table 
S2). Each weighted GRS was standardized per unit increase in the control population.  
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For each GRS we calculated the association with CM adjusted for sex, age and a list of traditional 
risk factors including eye color, hair color, skin color, phototype (according to the Fitzpatrick 
scale) and tanning ability. In case of missing values of the predictors we created an indicator 
variable for missingness and that was incorporated into the model as a separate covariate. We also 
performed a sensitivity analysis including only sex, age and the relevant GRS and an analysis 
limited to variables with non-missing values.  
 
We also assessed the performance of the predictive capability of the GRS by calculating the 
AUC. The AUC was calculated based on the covariates described above with and without the 
GRS. Bootstrapping (n=1,000) was used to calculate the p-values for the comparisons of the 
AUCs. In order to assess the internal validity of our predictive models we calculated the root 
mean square error, which error represents the differences between predicted and observed values, 
in 5-fold validation splits with 1,000 replications. Small values with a narrow range indicates 
good validation. The calibration of the model was also assessed by calculating the distribution of 
expected values and compared with the observed ones using Hosmer-Lemeshow test. 
 
Finally, quantiles of the GRS were created and ORs were calculated and compared in 5 different 
categories using the 3
rd
 category as a reference. Moreover, we stratified the dataset into quartiles 
of age (i.e. age at onset for cases and age at examination for controls) and we calculated the OR 
within each age group. 
 
Reporting of study results 
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The report followed the recommendations by two consensus publications aiming to enhance the 
quality of articles focusing on multivariable and genetic risk prediction models, i.e. the 
Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis 
(TRIPOD) statement (Collins et al., 2015) and the Genetic Risk Prediction Studies (GRIPS) 
statement (Janssens et al., 2011) respectively. 
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Table 1. Statistical significant results from the univariable analysis of the 53 eligible SNPs.  
 Univariable Analysis  
SNP Nearest Gene
1
 MAF P OR (95% CI) Function 
rs12918773 (CDK10) 0.031 1.63x10-6 2.28 (1.61, 3.22) Pigmentation 
rs16891982 SLC45A2 0.135 3.82x10
-6
 0.59 (0.47, 0.74) Pigmentation 
rs1805007 MC1R 0.024 8.22x10
-6
 2.34 (1.59, 3.43) Pigmentation 
rs11547464 MC1R 0.009 1.04x10
-4
 3.13 (1.71, 5.75) Pigmentation 
rs401681 CLPTM1L 0.416 2.23x10
-4
 1.30 (1.13, 1.50) Nevi 
rs12913832 HERC2 0.368 7.78x10
-4
 1.28 (1.11, 1.47) Pigmentation 
rs1805005 MC1R 0.141 2.56x10-3 1.34 (1.11, 1.62) Pigmentation 
rs1885120 MYH7B 0.019 3.09x10
-3
 1.94 (1.24, 3.04) Pigmentation 
rs35390 SLC45A2 0.089 3.46x10
-3
 0.67 (0.51, 0.88) Pigmentation 
rs10739221
2
 
(TMEM38B, ZNF462, 
RAD23B) 
0.271 0.015 1.21 (1.04, 1.41) Intergenic locus 
rs4778138
2
 OCA2 0.370 0.014 0.83 (0.72, 0.96) Pigmentation 
rs3768080 NID1 0.4095 0.026 1.17 (1.02, 1.35) Basement membrane 
rs10931936 CASP8 0.307 0.030 1.18 (1.02, 1.37) Apoptosis 
rs17119490 LOC101927549 0.01757 0.033 1.67 (1.04, 2.68) Intergenic locus 
rs4636294 MTAP 0.4044 0.030 0.85 (0.74, 0.98) Nevi 
Abbreviations: MAF=minor allelic frequency, OR=Odds Ratio, CI=Confidence Intervals 
  1“Nearest Gene” denotes the gene in the respective locus or one proximal gene in the respective locus (denoted with parenthesis) if the SNP itself does not map into a gene region. 
It should be noted that these genes are not necessarily the genes that are functionally affected by the genetic association finding in this locus. 
     2SNPs derived from GWAS meta-analysis (Law et. al, 2015) and replicated to our cohort. 
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Table2. Risk prediction performance for the four different models of predictors in the Greek data set. 
 AUC 95% CI 
Phenotypic Risk factors only
1
 0.764 0.741-0.787 
Phenotypic Risk factors + GRSGWS 0.775 0.752-0.797 
Phenotypic Risk factors + GRSALL 0.775 0.752-0.798 
Abbreviations: AUC, area under the receiver operating characteristic curve, CI=Confidence Intervals, 
GRS=genetic risk score, 1Risk factors= sex, age, eye color, hair color, skin color, phototype and tanning 
ability. 
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Figure Legends: 
1. Associations between GRS and melanoma in different quintile groups for GRSGWS and 
GRSALL. 
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Supplementary Table 1. Demographic characteristics and pigmentary phenotype of 
melanoma cases and control subjects. 
 Patients (n=800) Controls (n=800) P
1
 
Median age (years) (IQR; 
range) 
53 (41-66; 17-97) 41 (31-53; 19-80) 0.005 
Missing (N) 40 33  
Sex, N (%)   0.201 
Men 394 (49.25%) 408 (51.00%)  
Women 406 (50.75%) 365 (45.63%)  
Missing  0 27 (3.38%)  
Hair color   0.082 
Blonde 79 (9.88%)  47 (5.88%)  
Red 21 (2.63%)  25 (3.13%)  
Light Brown  216 (27.00%) 245 (30.63%)  
Dark Brown  278 (34.75%) 333 (41.63%)  
Black 74 (9.25%) 97 (12.13%)  
Missing  132 (16.50%) 53 (6.63%)  
Eye color   0.007 
Grey/Blue  87 (10.88%)  73 (9.13%)  
Green  144 (18.00%) 119 (14.88%)  
Light Brown 183 (22.88%) 226 (28.25%)  
Dark brown 232 (19.00%) 316 (39.50%)  
Black 3 (0.38%) 11 (1.38%)  
Missing 151 (18.88%) 55 (6.88%)  
Skin color   0.200 
White 372 (46.50%) 294 (36.75%)  
Light Brown  277 (34.63%) 325 (40.63%)  
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Dark 20 (2.50%) 124 (15.50%)  
Missing 131 (16.38%) 57 (7.13%)  
Phototype    0.075 
Phototype I 33 (4.13%) 43 (5.38%)  
Phototype II 303 (37.88%) 243 (30.38%)  
Phototype III 234 (29.25%) 316 (39.50%)  
Phototype IV 98 (12.25%) 127 (15.88%)  
Missing 132 (16.50%) 71 (8.88%)  
Tanning ability
2
   0.048 
Burn 96 (12%) 122 (15.25%)  
Minimal tan 287 (35.88%) 258 (32.25%)  
Burn than tan 207 (25.88%) 254 (31.75%)  
Deep tan 73 (9.13%) 81 (10.13%)  
Missing 137 (17.3%) 85 (10.63%)  
1Results from a Wilcoxon-Mann-Whitney test for the comparison of age between cases and controls; results from a 
chi-square test for the comparison of all other variables between cases and controls. 
2 Represents the answers to the question “How your skin reacts when you sunbathe during the first weeks of your 
vacation”. 
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Supplementary Table 2: Location, Original Source and Genotype Results of the 59 selected SNPs. 
SNP Chr BP Nearest Gene
1
 Minor 
Allele 
MAF P OR (95%CI) OR source/Selection source of 
SNP  
rs7412746
2 
1 150860471 LOC100996521 T 0.4768 0.1618 0.905 (0.787, 1.041) 1.14 MacGregor et al., 2011 
rs3219090 1 226564691 PARP1 A 0.3528 0.09918 0.883 (0.763, 1.024) 0.86 MelGene meta-analysis 
rs3768080 1 236179869 NID1 G 0.4095 0.02578 1.174 (1.019, 1.351) 1.07 Nan et al., 2011 
rs6750047
3
 2 38276549 RMDN2 A - - - - Law et al., 2015 
rs109319362 2 202143928 CASP8 T 0.307 0.02993 1.180 (1.016, 1.370) 1.15 MelGene meta-analysis 
rs1035142
2 
2 202153078 (ALS2CR12 and 
CASP8) 
T 0.4546 0.1466 1.109 (0.9644, 1.275) 1.14 MelGene meta-analysis 
rs1496179564 3 70014091 MITF      MelGene meta-analysis 
rs13097028
5
 3 169464942 (ACTRT3) T 0.2895 0.4274 0.939 (0.805, 1.096) 0.89 Song et al., 2014 
rs12696304 3 169481271 (TERC) G 0.2707 0.3378 0.926 (0.790, 1.084) 0.91 Law et al., 2015 
rs46989345 4 106139387 TET2 C 0.1335 0.4521 0.924 (0.751, 1.136) 0.85 Song et al., 2014 
rs401681
2 
5 1322087 CLPTM1L T 0.4159 0.000223 1.302 (1.132, 1.498) 1.19 MelGene meta-analysis 
rs16891982
2 
5 33951693 SLC45A2 C 0.1355 3.8x10
-6
 0.587 (0.467, 0.737) 0.42 MelGene meta-analysis 
rs35390
5
 5 33955326 SLC45A2 C 0.08908 0.003462 0.672 (0.515, 0.879) 0.36 Barrett et al., 2011 
rs12203592
5
 6 396321 IRF4 T 0.05451 0.4569 0.887 (0.648, 1.216) 1.16 MelGene meta-analysis 
rs8720715 6 411064 IRF4 G 0.4385 0.8636 1.012 (0.879, 1.165) 0.93 Barrett et al., 2011 
rs6914598
2 
6 21163919 CDKAL1 C 0.3331 0.6419 1.036 (0.894, 1.200) 1.10 Law et al., 2015 
rs1636744
2 
7 16984280 (AGR3) A 0.3695 0.8981 1.009 (0.874, 1.166) 1.09 Law et al., 2015 
rs1408799 9 12672097 (TYRP1) T 0.3319 0.4665 1.056 (0.912, 1.224) 0.91 MelGene meta-analysis 
rs4636294
2 
9 21747804 MTAP G 0.4044 0.03023 0.854 (0.739, 0.985) 0.83 MelGene meta-analysis 
rs10757257
2 
9 21806562 MTAP A 0.2976 0.06139 0.863 (0.739, 1.007) 0.81 MelGene meta-analysis 
rs7023329
2 
9 21816528 MTAP G 0.394 0.8437 0.986 (0.855, 1.137) 0.83 MelGene meta-analysis 
rs3088440 9 21968159 CDKN2A A 0.0801 0.515 1.087 (0.845, 1.397) 1.27 MelGene meta-analysis 
rs115155 9 21968199 CDKN2A G 0.1809 0.518 0.942 (0.784, 1.130) 1.05 MelGene meta-analysis 
rs1011970
5
 9 22062134 (CDKN2A) T 0.1769 0.1826 1.129 (0.944, 1.351) 1.18 Maccioni et al., 2013 
rs10739221
2 
9 109060830 (TMEM38B, T 0.271 0.01536 1.209 (1.037, 1.409) 1.13 Law et al., 2015 
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ZNF462, 
RAD23B) 
rs2995264
2 
10 105668843 OBFC1 G 0.1179 0.2326 1.137 (0.921, 1.403) 1.17 Law et al., 2015 
rs171194902 10 107522927 LOC101927549 A 0.01757 0.03287 1.668 (1.038, 2.683) 8.4 Teerlink et al., 2011 
rs1485993 11 69362414 (CCND1) T 0.4211 0.07393 1.137 (0.988, 1.308) 1.09 MelGene meta-analysis 
rs1042602 11 88911696 TYR A 0.4855 0.5016 1.049 (0.912, 1.206) 0.94 MelGene meta-analysis 
rs18471422 11 89021574 TYR A 0.2199 0.2166 1.110 (0.941, 1.310) 1.31 Bishop et al., 2009 
rs1801516
2 
11 108175462 ATM A 0.1395 0.1383 0.856 (0.696, 1.052) 0.84 MelGene meta-analysis 
rs1544410 12 48239835 VDR A 0.4266 0.6725 0.970 (0.843, 1.117) 0.9 MelGene meta-analysis 
rs17655 13 103528002 XPG G 0.2748 0.2088 0.904 (0.772, 1.058) 0.91 MelGene meta-analysis 
rs1800407 15 28230318 OCA2 A 0.06078 0.1572 1.223 (0.925, 1.616) 1.38 MelGene meta-analysis 
rs47781382 15 28355820 OCA2 G 0.3698 0.01417 0.833 (0.719, 0.964) 0.84 Law et al., 2015 
rs1129038
6
 15 28356859 HERC2 A - - - - Amos et al., 2011 
rs12913832
 
15 28365618 HERC2 G 0.3676 0.000778 1.276 (1.107, 1.471) 1.11 Amos et al., 2011 
rs169530023 16 54114824 FTO A - - - - Iles et al., 2013 
rs7188458
2 
16 89726484 C16orf55 A 0.3199 0.2367 1.094 (0.943, 1.268) 1.30 Bishop et al., 2009 
rs12918773
2 
16 89741403 (CDK10) A 0.03082 1.6x10
-6
 2.281 (1.615, 3.223) 1.87 Bishop et al., 2009 
rs258322
3
 16 89755903 CDK10 T - - - - MelGene meta-analysis 
rs1805005 16 89985844 MC1R T 0.1414 0.002556 1.339 (1.107, 1.619) 1.14 MelGene meta-analysis 
rs1805006 16 89985918 MC1R A 0.003145 0.2556 0.399 (0.077, 2.058) 1.53 MelGene meta-analysis 
rs2228479 16 89985940 MC1R A 0.04255 0.1566 1.266 (0.913, 1.755) 1.08 MelGene meta-analysis 
rs11547464
 
16 89986091 MC1R A 0.008794 0.000104 3.133 (1.707, 5.750) 1.47 MelGene meta-analysis 
rs18050072 16 89986117 MC1R T 0.02453 8.2x10-6 2.339 (1.594, 3.433) 1.8 MelGene meta-analysis 
rs1805009
2 
16 89986546 MC1R C 0.001252 0.4138 2.003 (0.366, 10.95) 1.89 MelGene meta-analysis 
rs4238833
2 
16 90050689 AFG3L1 G 0.3218 0.2432 1.092 (0.942, 1.266) 1.32 Bishop et al., 2009 
rs4785763
2 
16 90066936 AFG3L1 A 0.2972 0.1812 1.108 (0.953, 1.289) 1.35 MelGene meta-analysis 
rs8059973
2 
16 90079534 DBNDD1 A 0.1814 0.9167 1.010 (0.843, 1.209) 0.74 Bishop et al., 2009 
rs173056572 20 31806588 C20orf71 C 0.02324 0.2198 1.312 (0.849, 2.025) 1.58 Brown et al., 2008 
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rs4911414 20 32729444 (ASIP) T 0.2535 0.2643 0.912 (0.775, 1.072) 1.16 MelGene meta-analysis 
rs6058017
5 
20 32856998 ASIP G 0.1409 0.000412 1.406 (1.163, 1.699) 0.91 MelGene meta-analysis 
rs17305573
3
 20 33180152 PIGU C - - - -  
rs4911442 20 33355046 NCOA6 G 0.04887 0.05595 1.343 (0.992, 1.819) 1.28 MelGene meta-analysis 
rs1885120
2 
20 33576989 MYH7B C 0.01884 0.003086 1.944 (1.242, 3.041) 1.55 MelGene meta-analysis 
rs1015362
5
 20 37738612 (ASIP) A 0.2895 0.1906 0.902 (0.772, 1.053) 0.95 MelGene meta-analysis 
rs45430
2 
21 42746081 MX2 G 0.4143 0.1772 0.907 (0.787, 1.045) 0.88 Barrett et al., 2011 
rs6001027 22 38545619 PLA2G6 G 0.3785 0.8839 0.989 (0.857, 1.142) 0.86 MelGene meta-analysis 
Abbreviations: MAF=minor allelic frequency, OR=Odds Ratio, CI=Confidence Intervals, BP=base pairs, Chr=chromosome 
1“Nearest Gene” denotes the gene in the respective locus or one proximal gene in the respective locus (denoted with parenthesis) if the SNP itself does not map into a gene region. It should be noted that these 
genes are not necessarily the genes that are functionally affected by the genetic association finding in this locus. 
2SNPs included in the GRSGWS. 
3SNP not included in the analysis due to call rate<0.97. 
4SNP with rs149617956 was excluded from the analysis since it was monomorphic. 
5SNPs selected from MelGene due to their biological significance. 
6Deviation from Hardy-Weinberg equilibrium. 
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Supplementary Table 3. Risk allele frequency in the Greek sample and European sample from the 
1000 genomes (1KG) panel for the 53 eligible SNPs. 
SNP Risk allele in 
the Greek 
sample 
Risk allele frequency in the 
Greek sample (95% CI) 
Risk allele frequency in the 
EU sample from 1KG (95% 
CI) 
rs1011970 T 0.177 (0.15-0.203) 0.155 (0.122-0.188) 
rs1015362 G 0.711 (0.679-0.742) 0.723 (0.683-0.763) 
rs1035142 T 0.455 (0.42-0.489) 0.386 (0.342-0.429) 
rs1042602 A 0.486 (0.451-0.52) 0.372 (0.329-0.415) 
rs10739221 T 0.271 (0.24-0.302) 0.244 (0.205-0.282) 
rs10757257 G 0.702 (0.671-0.734) 0.612 (0.568-0.655) 
rs10931936 T 0.307 (0.275-0.339) 0.283 (0.243-0.323) 
rs11515 C 0.819 (0.792-0.846) 0.875 (0.845-0.905) 
rs11547464 A 0.009 (0.002-0.015) 0.009 (0.0002-0.018) 
rs12203592 C 0.945 (0.93-0.961) 0.884 (0.855-0.913) 
rs12696304 C 0.729 (0.699-0.76) 0.735 (0.695-0.774) 
rs12913832 G 0.368 (0.334-0.401) 0.636(0.593-0.679) 
rs12918773 A 0.031 (0.019-0.043) 0.084 (0.059-0.109) 
rs13097028 C 0.711 (0.679-0.742) 0.664 (0.623-0.706) 
rs1408799 T 0.332 (0.299-0.365) 0.346 (0.303-0.388) 
rs1485993 T 0.421 (0.387-0.455) 0.365 (0.322-0.408) 
rs1544410 G 0.573 (0.539-0.608) 0.596 (0.552-0.639) 
rs1636744 A 0.370 (0.336-0.403) 0.407 (0.363-0.451) 
rs16891982 G 0.865 (0.841-0.888) 0.938(0.916-0.960) 
rs17119490 A 0.018 (0.008-0.027) 0.011 (0.0008-0.021) 
rs17305657 C 0.023 (0.013-0.034) 0.065 (0.0425-0.087) 
rs17655 C 0.725 (0.694-0.756) 0.750 (0.711-0.789) 
rs1800407 A 0.061 (0.044-0.077) 0.076 (0.052-0.100) 
rs1801516 G 0.861 (0.836-0.885) 0.838 (0.805-0.871) 
rs1805005 T 0.141 (0.117-0.166) 0.112 (0.083-0.140) 
rs1805006 C 0.997 (0.993-1.00) 0.990 (0.980-0.999) 
rs1805007 T 0.025 (0.014-0.035) 0.072 (0.048-0.095) 
rs1805009 C 0.001 (-0.001-0.004) 0.008 (-0.0007-0.017) 
rs1847142 A 0.22 (0.191-0.249) 0.299 (0.258-0.340) 
rs1885120 C 0.019 (0.009-0.028) 0.042 (0.023-0.060) 
rs2228479 A 0.043 (0.029-0.057) 0.069 (0.04-0.092) 
rs2995264 G 0.118 (0.096-0.14) 0.089 (0.063-0.115) 
rs3088440 A 0.08 (0.061-0.099) 0.079 (0.054-0.103) 
rs3219090 G 0.647 (0.614-0.68) 0.676 (0.634-0.718) 
rs35390 A 0.911 (0.891-0.931) 0.965 (0.948-0.982) 
rs3768080 G 0.41 (0.375-0.444) 0.494 (0.449-0.538) 
rs401681 T 0.416 (0.382-0.45) 0.441 (0.397-0.485) 
rs4238833 G 0.322 (0.289-0.354) 0.322 (0.280-0.363) 
rs45430 A 0.586 (0.552-0.62) 0.622 (0.579-0.665) 
rs4636294 A 0.596 (0.562-0.63) 0.504 (0.459-0.549) 
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rs4698934 T 0.867 (0.843-0.89) 0.815 (0.780-0.849) 
rs4778138 A 0.63 (0.597-0.664) 0.831 (0.797-0.865) 
rs4785763 A 0.297 (0.266-0.329) 0.299 (0.258-0.340) 
rs4911414 G 0.747 (0.716-0.777) 0.700 (0.659-0.741) 
rs4911442 G 0.049 (0.034-0.064) 0.087 (0.06-0.113) 
rs6001027 A 0.622 (0.588-0.655) 0.636 (0.592-0.679) 
rs6058017 G 0.141 (0.117-0.165) 0.103 (0.075-0.130) 
rs6914598 C 0.333 (0.3-0.366) 0.313 (0.271-0.354) 
rs7023329 A 0.606 (0.572-0.64) 0.520 (0.475-0.564) 
rs7188458 A 0.32 (0.288-0.352) 0.393 (0.349-0.437) 
rs7412746 C 0.523 (0.489-0.558) 0.477 (0.432-0.521) 
rs8059973 A 0.181 (0.155-0.208) 0.183 (0.148-0.218) 
rs872071 G 0.439 (0.404-0.473) 0.474 (0.429-0.518) 
Abbreviations: CI=confidence intervals, N/A=not aplicable 
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Supplementary Table 4. Association between GRS and melanoma risk. 
 OR
1
 95% CI P 
GRSGWS 1.36 1.21-1.52 1.1x10
-7 
GRSALL 1.39 1.23-1.55 3.2x10
-8
 
Abbreviations: OR=Odds Ratio, CI=Confidence Intervals, GRS=genetic risk score. 
1OR for association between the GRS, coded as a continuous variable, and melanoma 
risk adjusted for sex, age, eye color, hair color, skin color, phototype and tanning ability. 
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Supplementary Table 5. Quintiles of GRSGWS , GRSALL. 
Analysis GRSGWS GRSGWS adjusted for risk factors 
Quintiles OR
1
 95% CI P OR
2
 95% CI P 
1 0.77 0.56-1.05 0.095 0.73 0.50-1.05 0.095 
2 1.01 0.74-1.38 0.937 1.03 0.70-1.50 0.881 
3 (ref) 1 . . 1 . . 
4 1.32 0.97-1.80 0.082 1.33 0.92-1.93 0.129 
5 1.72 1.26-2.36 0.001 1.88 1.29-2.74 0.001 
Analysis GRSALL GRSALL adjusted for risk factors 
1 0.65 0.49-0.91 0.007 0.59 0.48-0.87 0.007 
2 0.68 0.50-0.92 0.014 0.62 0.43-0.89 0.01 
3 (ref) 1 . . 1 . . 
4 1.09 0.80-1.49 0.579 1.17 0.81-1.67 0.404 
5 1.52 1.11-2.09 0.009 1.53 1.05-2.24 0.029 
Abbreviations:OR=Odds Ratio, CI=Confidence Intervals, GRS=genetic risk score 
1Odds ratios are for different quintiles of the genetic GRS relative to the middle quintile (40% to 60%) of the GRS 
2Odds ratios are for different quintiles of the genetic GRS relative to the middle quintile (40% to 60%) of the GRS, adjusted for 
sex, age, eye color, hair color, skin color, phototype and tanning ability  
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Supplementary Table 6. Association between GRS and melanoma risk in different age 
groups (quartiles of age).  
 GRSGWS GRSALL 
Age group
1
 OR
2
 (95% CI) P OR
2
 (95% CI) P 
<36 1.54 (1.21-1.98) 0.001 1.59 (1.20-2.08) 0.001 
36-47 1.43 (1.13-1.80) 0.003 1.37 (1.07-1.73) 0.012 
48-61 1.31 (1.04-1.64) 0.020 1.31 (1.05-1.63) 0.015 
>61 1.20 (0.93-1.54) 0.171 1.32 (1.01-1.72) 0.041 
 Interaction OR
3
 
(95% CI) 
 Interaction OR
3
 (95% 
CI) 
 
Interaction 
between GRS 
and age 
0.97 (0.91, 1.04)  0.98 (0.92, 1.05) 
 
Pinteraction 0.392  0.649  
Abbreviations: OR=Odds Ratio, CI=Confidence Intervals, GRS=genetic risk score 
1Age at diagnosis for melanoma patients, age at interview for controls. 
2OR for association between the GRS and melanoma risk adjusted for sex, age, eye color, hair color, skin 
color, phototype and tanning ability. 
3OR per 10 years for interaction between GRS and age. 
Each weighted GRS was standardized per unit increase in the control population. 
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Supplementary Figure 1. Correlation of the effect sizes found in the Greek sample and those  
derived from MelGene, original publication or the Law et al., 2015. 
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Supplementary Figure 2. Correlation of the risk allele frequencies found in the Greek sample  
and the frequencies of the same alleles from the European sample from the 1000 genomes (1KG) panel. 
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